Developmental switches regulating tissue cyst formation

调节组织囊肿形成的发育开关

基本信息

  • 批准号:
    9383727
  • 负责人:
  • 金额:
    $ 57.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2022-07-31
  • 项目状态:
    已结题

项目摘要

Project Summary Toxoplasma gondii infections continue to be a public health hazard for millions of individuals that contact this pathogen annually. More than 50 million individuals in the US are chronically infected with Toxoplasma gondii and thousands of healthy individuals develop eye disease due to this infection that can lead to permanent vision loss. The Centers for Disease Control and Prevention considers Toxoplasma one of the five most important neglected parasitic infections. Individuals can be reasonably treated (despite significant side effects) if clinical toxoplasmosis is presented, however, there is a lack of drugs to treat or prevent the tissue cyst that is responsible for long-term infections. This therapy failure leaves at-risk individuals who become infected vulnerable to disease relapse throughout their lifetimes. Understanding the developmental mechanisms responsible for tissue cyst formation are needed to develop therapies to combat life-long disease. The Toxoplasma biology that underlies chronic disease is a reversible transformation of the asexual replicating tachyzoite into the latent bradyzoite stage. This critical developmental transition is accompanied by significant changes in gene expression controlled by poorly defined transcriptional mechanisms. Recent experiments of our group have identified key cell cycle regulated and stress-induced Toxoplasma ApiAP2 factors that prevent or activate bradyzoite gene expression. We hypothesize these discoveries reveal a transcriptional network that directs the competing needs of tachyzoite growth against development of the dormant tissue cyst required for parasite transmission. To understand how this transcriptional network operates, we propose two specific aims: In Aim 1, the experimental focus will be ApiAP2 transcriptional repressors that are expressed in the second half of the tachyzoite cell cycle whose mechanisms we will define at the molecular level and characterize in cell culture and animal models of parasite development. In Aim 2, we will determine how the stress-induced ApiAP2 repressors and activators compete to control bradyzoite gene expression and determine how these mechanisms influence Toxoplasma development in the intermediate host.
项目摘要 弓形虫感染仍然是数百万接触过弓形虫的人的公共健康威胁。 每年都有病原体。美国超过5000万人慢性感染弓形虫 数以千计的健康人由于这种感染而患上眼病,这种感染可能导致永久性的 视力丧失。疾病控制和预防中心认为弓形虫是五大 重要的被忽视的寄生虫感染。个人可以得到合理的治疗(尽管有明显的副作用) 然而,如果出现临床弓形虫病,则缺乏治疗或预防组织囊肿的药物 对长期感染负责。这种治疗失败使感染的高危个体 易患疾病的人一生中都会复发。理解发育机制 负责组织囊肿形成的人需要开发与终身疾病作斗争的治疗方法。这个 弓形虫生物学是慢性疾病的基础,是无性复制的可逆转变 速殖子进入潜伏缓殖子阶段。这一关键的发展转型伴随着显著的 基因表达的变化由不明确的转录机制控制。最近的实验 我们的团队已经确定了关键的细胞周期调节和应激诱导的弓形虫ApiAP2因子,这些因子可以防止 或激活缓殖子基因的表达。我们假设这些发现揭示了转录网络 这使速殖子生长的竞争需求与所需的休眠组织囊的发展相对应。 用于寄生虫传播。为了了解这个转录网络是如何运作的,我们提出了两个具体的 目的:在目标1中,实验的重点将是ApiAP2转录抑制物,这些转录抑制物在 速殖子细胞周期的后半部分,我们将在分子水平和 在细胞培养和寄生虫发育的动物模型中具有特点。在目标2中,我们将确定 应激诱导的ApiAP2抑制子和激活子竞争控制缓殖子基因的表达和 确定这些机制如何影响中间宿主中的弓形虫发育。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michael W White其他文献

Michael W White的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michael W White', 18)}}的其他基金

Defining the cell and molecular basis of Toxoplasma recrudescence
定义弓形虫复发的细胞和分子基础
  • 批准号:
    10330031
  • 财政年份:
    2021
  • 资助金额:
    $ 57.07万
  • 项目类别:
Defining the cell and molecular basis of Toxoplasma recrudescence
定义弓形虫复发的细胞和分子基础
  • 批准号:
    10180280
  • 财政年份:
    2021
  • 资助金额:
    $ 57.07万
  • 项目类别:
Defining the cell and molecular basis of Toxoplasma recrudescence
定义弓形虫复发的细胞和分子基础
  • 批准号:
    10540764
  • 财政年份:
    2021
  • 资助金额:
    $ 57.07万
  • 项目类别:
Developmental switches regulating tissue cyst formation
调节组织囊肿形成的发育开关
  • 批准号:
    10217990
  • 财政年份:
    2017
  • 资助金额:
    $ 57.07万
  • 项目类别:
Developmental switches regulating tissue cyst formation
调节组织囊肿形成的发育开关
  • 批准号:
    9980272
  • 财政年份:
    2017
  • 资助金额:
    $ 57.07万
  • 项目类别:
Studies of DNA Licensing in Apicomplexa Parasites
顶复门寄生虫 DNA 许可的研究
  • 批准号:
    9196820
  • 财政年份:
    2016
  • 资助金额:
    $ 57.07万
  • 项目类别:
Centrosome control of Toxoplasma growth
弓形虫生长的中心体控制
  • 批准号:
    8643435
  • 财政年份:
    2013
  • 资助金额:
    $ 57.07万
  • 项目类别:
Centrosome control of Toxoplasma growth
弓形虫生长的中心体控制
  • 批准号:
    9185938
  • 财政年份:
    2013
  • 资助金额:
    $ 57.07万
  • 项目类别:
The AP2 factors required for Toxoplasma replication
弓形虫复制所需的 AP2 因子
  • 批准号:
    8265918
  • 财政年份:
    2011
  • 资助金额:
    $ 57.07万
  • 项目类别:
The AP2 factors required for Toxoplasma replication
弓形虫复制所需的 AP2 因子
  • 批准号:
    8811088
  • 财政年份:
    2011
  • 资助金额:
    $ 57.07万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 57.07万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 57.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 57.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 57.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 57.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 57.07万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 57.07万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 57.07万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 57.07万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 57.07万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了